Yayi He
Clinical trials sponsored by Yayi He, explained in plain language.
-
New drug cocktail aims at resistant lung cancer
Disease control Not yet recruitingThis phase 2 trial tests whether combining two drugs, lomustine and anlotinib, can shrink tumors or slow disease in people with extensive-stage small cell lung cancer that has not responded to at least two prior treatments. About 46 participants will receive the drug combination …
Phase 2 • Sponsor: Yayi He • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New cocktail of immunotherapy, targeted drug, chemo, and radiation takes on lung cancer
Disease control Not yet recruitingThis phase 2 trial is testing a powerful combination of treatments for people with limited-stage small cell lung cancer (LS-SCLC) who have not had prior therapy. Participants will receive an immunotherapy drug (benmelstobart), an anti-angiogenic pill (anlotinib), standard chemoth…
Phase 2 • Sponsor: Yayi He • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New hope for advanced lung cancer: combo therapy targets tough tumors
Disease control Not yet recruitingThis study tests a new treatment for people with extensive-stage small cell lung cancer (ES-SCLC) who haven't had treatment before. It combines an immunotherapy drug (benmelstobart), a targeted therapy (anlotinib), and chemotherapy, followed by chest radiation. The goal is to see…
Phase 2 • Sponsor: Yayi He • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC